Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.56 |
| ▸ | NOS1 | P29475 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetophenone SCHEMBL28866763 | 0.89 | MAPT (0.54) | NOS3NOS1SMN1; SMN2MAPTHPGD | |
| SCHEMBL2206586 | 0.81 | HTT (0.62) | SMN1; SMN2HTTMAPTLMNA | |
| SCHEMBL50646 | 0.81 | MAPT (0.68) | NOS3NOS1SMN1; SMN2MAPTHPGD | |
| SCHEMBL2304015 | 0.79 | PARP1 (0.55) | NOS1SMN1; SMN2HTTMAPTL3MBTL1 | |
| SCHEMBL1718746 | 0.79 | NOS1 (0.60) | NOS3NOS1SMN1; SMN2MAPTHPGD | |
| Acetophenone SCHEMBL7141951 | 0.78 | MAPT (0.58) | NOS3NOS1SMN1; SMN2MAPTHPGD | |
| SCHEMBL6888913 | 0.78 | ALDH1A1 (0.51) | SMN1; SMN2MAPTHPGDRAB9ALMNA | |
| Hydrochloric Acid SCHEMBL4372446 | 0.77 | NOS1 (0.61) | NOS3NOS1SMN1; SMN2MAPTHPGD | |
| SCHEMBL1972179 | 0.77 | TSHR (0.63) | SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL29138676 | 0.77 | MAPT (0.56) | NOS3NOS1SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| US-9242009-B2 | Compositions and methods to treat neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150209438-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2015-07-30 | — | — | US | disclosed |
| WO-2014015047-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209438-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | PSEN2, SNCA, PSEN1 | NOS3 1299/4885NOS1 1874/4885SMN1; SMN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.